- Published at
- by manilatimes.net
mixed
mixed
News for AstraZeneca PLC (AZN)
- Published at
- by finance.yahoo.com
mixedmixed- Published at
- by gurufocus.com
positivepositive- Published at
- by ft.com
positivepositiveWallenbergs step up succession pace with board appointments
Roles announced for members of sixth generation of Swedish industrialists- Published at
- by seekingalpha.com
negativenegativeAstraZeneca meets main goal in late stage gastric cancer treatment trial (AZN:NASDAQ)
AstraZeneca's gastric cancer treatment, IMFINZI, demonstrated a statistically significant improvement in the primary endpoint. Read more here.- Published at
- by zacks.com
neutralneutralAstrazeneca (AZN) Stock Moves -0.63%: What You Should Know
In the closing of the recent trading day, Astrazeneca (AZN) stood at $77.47, denoting a -0.63% change from the preceding trading day.- Published at
- by benzinga.com
mixedmixedAmgen Challenges Novo Nordisk and Eli Lilly As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
Amgen Inc. AMGN has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the...- Published at
- by manilatimes.net
positivepositiveOlverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), for combination with low-intensity chemotherapy for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).- Published at
- by seekingalpha.com
neutralneutralAstraZeneca: A Big Pharma Blue Chip To Buy Now (NASDAQ:AZN)
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.- Published at
- by gurufocus.com
neutralneutral/C O R R E C T I O N -- Compugen Ltd./
PR NewswireHOLON, Israel, March 4, 2025 In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd- Published at
- by gurufocus.com
mixedmixedCompugen Reports Fourth Quarter and Full Year 2024 Results
PR NewswireHOLON, Israel, March 4, 2025 Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG an- Published at
- by gurufocus.com
positivepositiveSPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlook Therapeutics Inc.
Overview of the Recent Transaction On January 17, 2025, SPHERA FUNDS MANAGEMENT LTD. (Trades, Portfolio) made a strategic move by acquiring 1,714,284 shares of- Published at
- by seekingalpha.com
neutralneutralDaiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment- Published at
- by gurufocus.com
positivepositiveCauseway International Value's Strategic Moves: A Closer Look at Nintendo Co Ltd
Insights from the Fourth Quarter of 2024 Causeway International Value (Trades, Portfolio) recently submitted its N-PORT filing for the fourth quarter of 2024,- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
mixedmixedCompugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
PR NewswireHOLON, ISRAEL, March 3, 2025 HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer im- Published at
- by gurufocus.com
mixedmixedArtelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
Multiple Clinical Readouts Due in 2025 SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( ARTL), a clinical-stage pharmaceu- Published at
- by insidermonkey.com
mixedmixedIs Pfizer Inc. (PFE) the Best Weight Loss Drug Stock to Buy According to Analysts?
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc.- Published at
- by insidermonkey.com
positivepositiveIs AstraZeneca PLC (AZN) The Best Immunology Stock To Buy Now?
We recently published a list of 10 Best Immunology Stocks To Buy Now.- Published at
- by gurufocus.com
neutralneutralAstraZeneca's TEZSPIRE Shows Promising Results in Phase III WAYPOINT Trial for Nasal Polyps
AstraZeneca PLC (AZN) announced the full results from the Phase III WAYPOINT trial, demonstrating that TEZSPIRE® (tezepelumab-ekko), developed in collaboration